Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Induction response and remission rates (%)

From: Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden

  First induction dose Second induction dose
Response Remission Response Remission
Conventional care failure
 Ustekinumab 55.5 34.9 64.9 44.9
 Adalimumab 54.8 45.6 43.0 28.0
TNF-alpha inhibitor failure
 Ustekinumab 33.7 18.5 41.1 18.4
 Vedolizumab 32.7 12.9 16.0 6.8
  1. TNF tumour necrosis factor